,,paladin,,I am sure there have been resets in different ways for RVX that we are not aware of but it has not stopped a great number of biotechs to perform trials in 2020,,,,to make incredible deals in 2020 ,,to list their IPO on a US exchange in 2020 or other,,,,in fact it should have given management ample time to reflect,,,,,,, look at the biotech space in general,,,,one year TTR for ETFs are mostly up well over 50% not taking into account the April lows experienced,,,,,,,,many junior companies with absoluitely no intrinsic value have well out performed this dog!!,,its a fact,,,,,and that rests square on the shoulders of DMcC. Big responsibility comes with big pay,,not sure what is not to understand with that!,,the market sees how irresponsible the RVX team is in developing and safe guarding shareholder value. That should be very obvious at this point. Insiders and special friends have a large advantage,,we however have to use a rosetta stone to even try to best guess what comes next!!! We need seasoned and experienced negotiations,,input that is unbiased to the future if we do have one. As well noted by other posters our inventory is becoming stale and our message redundant. jmo